Dear NCCN Acute Myeloid Leukemia Guidelines Panel:

On behalf of Stemline Therapeutics, Inc., I respectfully submit the enclosed information to the National Comprehensive Cancer Network (NCCN) Acute Myeloid Leukemia (AML) panel:

ELZONRIS™ (tagraxofusp) in patients with blastic plasmacytoid dendritic-cell neoplasm (BPDCN) ¹ ²


Please consider the above publication published in the *New England Journal of Medicine* describing results from the clinical trial of ELZONRIS (tagraxofusp) in patients with BPDCN as supporting materials for the December 13, 2018 request for inclusion of ELZONRIS (tagraxofusp) in the NCCN clinical practice guidelines in AML.

We appreciate the opportunity to provide this additional information for review by the NCCN AML Panel. If you have any questions or need additional information, please do not hesitate to contact me at 1-646-502-1389 or via e-mail at dsieminski@stemline.com.

Thank you for your time and consideration.

Sincerely,

Debra Sieminski, MS, PA-C
Medical Affairs

Reference(s):